Dinaciclib | CDK inhibitor

Dinaciclib chemical structure

Available Options

Size:PriceQuantity 
5 mg$60.00
25 mg$225.00
Request Quote / Bulk / Custom Size
Product Inquiry

Dinaciclib (779353-01-4) is a potent and selective inhibitor of cyclin-dependent kinases CDK1, CDK2, CDK5, and CDK9 (IC50s respectively: 3 nM, 1 nM, 1 nM, and 4 nM).1,2 Active across multiple human cancer cell lines and in mouse xenograft models.3-9

References/Citations:

  1. Paruch et al. (2010), Discovery of Dinaciclib (SCH 727965): A potent and Selective Inhibitor of Cyclin-Dependent Kinase; ACS Med. Chem. Lett., 1 204
  2. Parry et al. (2010), Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor; Mol. Cancer Ther., 9 2344
  3. Saqub et al. (2020), Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by target CDK2/5/9; Sci. Rep., 10 18489
  4. Howard et al. (2021), Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer; Cancers (Basel)., 13 1135
  5. Buzzetti et al. (2021), Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells; Sci. Rep., 11 5374
  6. Nelson et al. (2022), Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal carcinoma; Cell Cycle, 21 1103
  7. Howard et al. (2022), Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum-resistant ovarian cancer; Front. Oncol., 12 1014280
  8. Schott et al. (2024), Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metathesis Inhibition by Dinaciclib through a Genome-Targeted Approach; Clin. Cancer Res., 30 849
  9. Valdez Capuccino et al. (2024), CDK9 inhibition as an effective therapy for small cell lung cancer; Cell Death Dis., 15 345
779353-01-4, CAS 779353-01-4, CDK inhibitor, CDK1 inhibitor, CDK2 inhibitor, CDK5 inhibitor, CDK9 inhibitor, dinaciclib, Dinaciclib supplier, SCH 727965, SCH727965
Alternate Name:
SCH 727965

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

Dinaciclib (779353-01-4) is a potent and selective inhibitor of cyclin-dependent kinases CDK1, CDK2, CDK5, and CDK9 (IC50s respectively: 3 nM, 1 nM, 1 nM, and 4 nM).1,2 Active across multiple human cancer cell lines and in mouse xenograft models.3-9

References/Citations:

  1. Paruch et al. (2010), Discovery of Dinaciclib (SCH 727965): A potent and Selective Inhibitor of Cyclin-Dependent Kinase; ACS Med. Chem. Lett., 1 204
  2. Parry et al. (2010), Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor; Mol. Cancer Ther., 9 2344
  3. Saqub et al. (2020), Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by target CDK2/5/9; Sci. Rep., 10 18489
  4. Howard et al. (2021), Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer; Cancers (Basel)., 13 1135
  5. Buzzetti et al. (2021), Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells; Sci. Rep., 11 5374
  6. Nelson et al. (2022), Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal carcinoma; Cell Cycle, 21 1103
  7. Howard et al. (2022), Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum-resistant ovarian cancer; Front. Oncol., 12 1014280
  8. Schott et al. (2024), Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metathesis Inhibition by Dinaciclib through a Genome-Targeted Approach; Clin. Cancer Res., 30 849
  9. Valdez Capuccino et al. (2024), CDK9 inhibition as an effective therapy for small cell lung cancer; Cell Death Dis., 15 345